CN111741753A - 治疗高甘油三酯血症的方法 - Google Patents

治疗高甘油三酯血症的方法 Download PDF

Info

Publication number
CN111741753A
CN111741753A CN201880089648.7A CN201880089648A CN111741753A CN 111741753 A CN111741753 A CN 111741753A CN 201880089648 A CN201880089648 A CN 201880089648A CN 111741753 A CN111741753 A CN 111741753A
Authority
CN
China
Prior art keywords
patient
subject
week
hdl
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201880089648.7A
Other languages
English (en)
Chinese (zh)
Inventor
G·戈登
大岛隆
末平和人
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kowa Co Ltd
Original Assignee
Kowa Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kowa Co Ltd filed Critical Kowa Co Ltd
Publication of CN111741753A publication Critical patent/CN111741753A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4168—1,3-Diazoles having a nitrogen attached in position 2, e.g. clonidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/423—Oxazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201880089648.7A 2017-12-21 2018-12-20 治疗高甘油三酯血症的方法 Pending CN111741753A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762609048P 2017-12-21 2017-12-21
US62/609,048 2017-12-21
PCT/US2018/066976 WO2019126597A1 (en) 2017-12-21 2018-12-20 Methods of treatment of hypertrigl yceridemia

Publications (1)

Publication Number Publication Date
CN111741753A true CN111741753A (zh) 2020-10-02

Family

ID=66995099

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880089648.7A Pending CN111741753A (zh) 2017-12-21 2018-12-20 治疗高甘油三酯血症的方法

Country Status (9)

Country Link
US (1) US20190224169A1 (enExample)
EP (1) EP3727376A4 (enExample)
JP (2) JP2021506907A (enExample)
CN (1) CN111741753A (enExample)
AU (1) AU2018393119B2 (enExample)
CA (1) CA3085951C (enExample)
MY (1) MY205171A (enExample)
SG (1) SG11202005850VA (enExample)
WO (1) WO2019126597A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250034041A (ko) * 2022-07-15 2025-03-10 교와 가부시키가이샤 혈중 ldl 콜레스테롤 저하제
WO2024167964A1 (en) * 2023-02-08 2024-08-15 Kowa Company, Ltd. Methods of treating and preventing peripheral artery disease
WO2025069226A1 (ja) * 2023-09-26 2025-04-03 興和株式会社 ペマフィブラートを含有する医薬

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2004270538C1 (en) * 2003-09-03 2010-01-14 Kowa Co., Ltd PPAR-activating compound and pharmaceutical composition containing same
TWI407955B (zh) * 2007-03-29 2013-09-11 Kowa Co 高脂血症之預防及／或治療劑
MY177686A (en) * 2012-09-27 2020-09-23 Kowa Co Therapeutic agent for dyslipidemia
SG11201610243YA (en) * 2014-06-26 2017-01-27 Cymabay Therapeutics Inc Treatment of severe hypertriglyceridemia
TWI691331B (zh) * 2014-09-26 2020-04-21 日商興和股份有限公司 脂質異常症治療劑
RS61403B1 (sr) 2016-07-29 2021-02-26 Kowa Co Postupci prevencije kardiovaskularnih događaja u populacijama sa dislipidemijom sa rezidualnim rizikom

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
ISHIBASHI S 等: "Efficacy and safety of pemafibrate (K-877), a selective peroxisome proliferator-activated receptor α modulator, in patients with dyslipidemia: Results from a 24-week, randomized, double blind, active-controlled, phase 3 trial.", Retrieved from the Internet <URL:https://europepmc.org/article/med/29203092> *
JEAN CHARLES FRUCHART: "Pemafbrate (K-877), a novel selective peroxisome proliferator-activated receptor alpha modulator for management of atherogenic dyslipidaemia", CARDIOVASC DIABETOL, vol. 16, 4 October 2017 (2017-10-04), pages 124 *
SHUN ISHIBASHI 等: "Effects of K-877, a novel selective PPARa modulator (SPPARMa), in dyslipidaemic patients: A randomized, double blind, active- and placebo-controlled, phase 2 trial", ATHEROSCLEROSIS, vol. 249, 26 February 2016 (2016-02-26), pages 36 - 43, XP055928402 *
林曙光: "心脏病学进展.2014", vol. 1, 30 April 2014, 人民军医出版社, pages: 225 - 227 *
范建高等: "中国脂肪肝防治指南：科普版", vol. 1, 31 March 2015, 上海科学技术出版社, pages: 122 - 123 *

Also Published As

Publication number Publication date
AU2018393119A1 (en) 2020-07-23
AU2018393119B2 (en) 2022-08-25
CA3085951A1 (en) 2019-06-27
MY205171A (en) 2024-10-04
US20190224169A1 (en) 2019-07-25
JP2021506907A (ja) 2021-02-22
JP2023181451A (ja) 2023-12-21
EP3727376A4 (en) 2021-07-21
SG11202005850VA (en) 2020-07-29
WO2019126597A1 (en) 2019-06-27
CA3085951C (en) 2022-10-11
EP3727376A1 (en) 2020-10-28

Similar Documents

Publication Publication Date Title
US20210069158A1 (en) Methods of Preventing Occurrence of Cardiovascular Events
US10449154B2 (en) Treatment of NASH with Gemcabene
JP2023181451A (ja) 高トリグリセライド血症の治療方法
CN108685889A (zh) 用于治疗特征为心房增大或重构的疾病的nep抑制剂
NO320745B1 (no) Farmasoytisk medikament-kombinasjoner omfattende (E)-7-[4-(4-fluorfenyl)-6-isopropyl-2-[metyl-(metylsulfonyl)-amino]-pyrimidin-5-yl]-(3R,5S)-3,5-dihydroksy-hept-6-ensyre og en inhibitor, inducer eller substrat av P450 isoenzym 3A4 samt anvendelse derav
US11331292B2 (en) Methods of treatment of cholestatic diseases
US12295927B2 (en) Methods of treatment of cholestatic diseases
US11446282B2 (en) Methods of treating mixed dyslipidemia and hypertriglycertdemia
TWI741379B (zh) 藥物組成物與包含膽固醇酯轉移蛋白抑制劑和HMG CoA還原酶抑制劑的治療組合
TWI651086B (zh) 用以治療或預防心血管疾病之膽固醇酯轉蛋白質(cetp)抑制劑及包含該抑制劑之醫藥組成物
Aguilar-Salinas et al. Ciprofibrate versus gemfibrozil in the treatment of mixed hyperlipidemias: an open-label, multicenter study
Insull Jr et al. Effects of raloxifene and low-dose simvastatin coadministration on plasma lipids in postmenopausal women with primary hypercholesterolemia
WO2019004465A1 (ja) ペマフィブラートを含有する医薬
CN110996937A (zh) 包含dgla的药物组合物及其用途
Okunevich Short report of original clinical trial of neurotropic drug: L-dopa efficiency of using in therapy of coronary artery disease
Juhász et al. Cardiovascular risk factors in newly diagnosed, untreated Hungarian patients with familial hypercholesterolemia
CN118001273A (zh) 血脂异常治疗剂
Tingley et al. GW24-e2907 Effects of RG7652, a fully human mAb against proprotein convertase subtilisin/kexin type 9, on LDL-c: a Phase I, randomised, double-blind, placebo-controlled, single-and multiple-dose study
Raj et al. Comparative Study of Rosuvastatin as Monotherapy Versus Rosuvastatin with Ramipril in Dyslipidemia and Their Effects on Atherosclerosis

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination